Effects of the benzodiazepine inverse agonist RO19-4603 alone and in combination with the benzodiazepine receptor antagonists flumazenil, ZK 93426 and CGS 8216, on ethanol intake in alcohol-preferring (P) rats.
The present study investigated dose dependence and time course effects of the benzodiazepine (BDZ) partial inverse agonist, RO19-4603 (0.005-0.30 mg/kg) alone, and in combination with the BDZ receptor antagonists flumazenil, ZK 93426, and CGS 8216 (20 mg/kg) in selectively bred alcohol-preferring (P) rats provided a two-bottle choice test between ethanol (EtOH) (10% v/v), and a palatable saccharin (0.0125% g/v) solution. A single dose of RO19-4603 as low as 0.009 mg/kg selectively reduced EtOH drinking during the initial 15 min of a 4 h access to 19-0% of control levels on day 1. The 0.08, 0.15 and 0.30 mg/kg doses of RO19-4603 significantly reduced total EtOH intake in the 4 h access period to 57-45% of controls on day 1. On day 2, no RO19-4603 injections were given; however, six of the seven doses of RO19-4603 (0.009, 0.02, 0.04, 0.08, 0.15, and 0.30 mg/kg) continued to reduce EtOH intake to 42-3% of control levels at the initial 15 min interval, while the 0.005, 0.009, 0.08, and 0.30 mg/kg doses reduced total 4 h EtOH intake to 60-42% of controls. Saccharin intake was either not altered by RO19-4603 or showed increases during the initial 15 min intervals and the total 4 h sessions on days 1 and 2. Food intake was also unaffected by RO19-4603. The CGS 8216, but neither flumazenil nor ZK 93426, reliably reversed the RO19-4603-induced suppression of EtOH intake on days 1 and 2. That certain BDZ inverse agonists can attenuate motivated behavior for EtOH reinforcement over a prolonged time course may provide a possible therapeutic approach to reducing EtOH consumption associated with alcoholism.
June
H L
HL
Department of Psychology, Purdue School of Science, Indiana University-Purdue University, Indianapolis 46202, USA. hjune@indyvax.iupui.edu
Greene
T L
TL
Murphy
J M
JM
Hite
M L
ML
Williams
J A
JA
Cason
C R
CR
Mellon-Burke
J
J
Cox
R
R
Duemler
S E
SE
Torres
L
L
Lumeng
L
L
Li
T K
TK
D000428:Alcohol Drinking; D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D001569:Benzodiazepines / Q000819:agonists*; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D004338:Drug Combinations; D004435:Eating / Q000187:drug effects; D000431:Ethanol; D005260:Female; D005442:Flumazenil / Q000494:pharmacology*; D058787:GABA-A Receptor Antagonists; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D012439:Saccharin; D012996:Solutions; D013997:Time Factors
D001381:Azepines; D004338:Drug Combinations; D058787:GABA-A Receptor Antagonists; D011720:Pyrazoles; D012996:Solutions; D001569:Benzodiazepines; D000431:Ethanol; D005442:Flumazenil; C033830:2-phenylpyrazolo(4,3-c)quinolin-3(5H)-one; C056530:Ro 19-4603; D012439:Saccharin